Lunresertib

N/A

Report date: 2026/04/28 20:00:22
NME

Base Information

Drug NameLunresertib
Drug Alias NameCCNE1-SL inhibitor - Repare TherapeuticsManchesterRP-6306
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase inhibitors
TargetsMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisUterine Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesUnited Kingdom +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesRepare Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesRepare Therapeutics IncUniversity Health Network (Uhn)
Inactive CompaniesDebiopharm International Sa
Active IndicationsNeoplasm MetastasisUterine NeoplasmsOvarian Neoplasms +[4] 
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A